CEBPD | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
fibroblast	46 studies	57% ± 23%	Explore
macrophage	39 studies	53% ± 23%	Explore
endothelial cell	39 studies	45% ± 19%	Explore
pericyte	37 studies	58% ± 27%	Explore
classical monocyte	29 studies	59% ± 19%	Explore
smooth muscle cell	27 studies	53% ± 27%	Explore
conventional dendritic cell	26 studies	55% ± 17%	Explore
natural killer cell	24 studies	35% ± 15%	Explore
dendritic cell	23 studies	49% ± 21%	Explore
monocyte	23 studies	46% ± 21%	Explore
non-classical monocyte	23 studies	53% ± 19%	Explore
endothelial cell of lymphatic vessel	21 studies	54% ± 24%	Explore
basal cell	21 studies	57% ± 20%	Explore
epithelial cell	18 studies	47% ± 22%	Explore
ciliated cell	17 studies	42% ± 23%	Explore
connective tissue cell	16 studies	53% ± 21%	Explore
myeloid cell	15 studies	51% ± 22%	Explore
capillary endothelial cell	14 studies	41% ± 20%	Explore
myofibroblast cell	13 studies	51% ± 27%	Explore
mucosal invariant T cell	12 studies	24% ± 8%	Explore
microglial cell	12 studies	38% ± 16%	Explore
endothelial cell of vascular tree	12 studies	60% ± 25%	Explore
type II pneumocyte	11 studies	61% ± 24%	Explore
neutrophil	11 studies	45% ± 16%	Explore
secretory cell	11 studies	59% ± 21%	Explore
mesothelial cell	11 studies	48% ± 23%	Explore
vein endothelial cell	11 studies	46% ± 21%	Explore
type I pneumocyte	10 studies	40% ± 20%	Explore
club cell	10 studies	46% ± 23%	Explore
endothelial cell of artery	9 studies	50% ± 20%	Explore
astrocyte	9 studies	35% ± 14%	Explore
CD16-positive, CD56-dim natural killer cell, human	8 studies	32% ± 9%	Explore
CD16-negative, CD56-bright natural killer cell, human	8 studies	35% ± 16%	Explore
T cell	7 studies	24% ± 7%	Explore
mononuclear phagocyte	7 studies	62% ± 19%	Explore
abnormal cell	7 studies	39% ± 21%	Explore
leukocyte	7 studies	46% ± 15%	Explore
innate lymphoid cell	7 studies	29% ± 12%	Explore
respiratory goblet cell	6 studies	42% ± 21%	Explore
intermediate monocyte	6 studies	59% ± 28%	Explore
ionocyte	5 studies	46% ± 16%	Explore
Mueller cell	5 studies	39% ± 9%	Explore
alveolar macrophage	4 studies	21% ± 5%	Explore
glomerular endothelial cell	4 studies	42% ± 9%	Explore
epithelial cell of proximal tubule	4 studies	26% ± 10%	Explore
enterocyte	4 studies	24% ± 4%	Explore
adventitial cell	4 studies	73% ± 12%	Explore
glial cell	4 studies	30% ± 7%	Explore
luminal hormone-sensing cell of mammary gland	4 studies	70% ± 11%	Explore
luminal cell of prostate epithelium	4 studies	57% ± 11%	Explore
hepatocyte	4 studies	42% ± 20%	Explore
gamma-delta T cell	4 studies	19% ± 1%	Explore
keratinocyte	4 studies	42% ± 22%	Explore
duct epithelial cell	3 studies	41% ± 2%	Explore
hillock cell	3 studies	48% ± 13%	Explore
monocyte-derived dendritic cell	3 studies	81% ± 11%	Explore
progenitor cell	3 studies	28% ± 10%	Explore
kidney loop of Henle epithelial cell	3 studies	46% ± 13%	Explore
renal principal cell	3 studies	47% ± 10%	Explore
extravillous trophoblast	3 studies	54% ± 13%	Explore
placental villous trophoblast	3 studies	51% ± 6%	Explore
retinal pigment epithelial cell	3 studies	29% ± 7%	Explore
adipocyte	3 studies	24% ± 7%	Explore
tissue-resident macrophage	3 studies	58% ± 20%	Explore
myoepithelial cell	3 studies	64% ± 19%	Explore
inflammatory macrophage	3 studies	41% ± 8%	Explore
muscle cell	3 studies	47% ± 16%	Explore
acinar cell	3 studies	44% ± 20%	Explore
hematopoietic precursor cell	3 studies	29% ± 6%	Explore
mucus secreting cell	3 studies	49% ± 25%	Explore
group 3 innate lymphoid cell	3 studies	23% ± 2%	Explore
progenitor cell of mammary luminal epithelium	3 studies	58% ± 20%	Explore
mature NK T cell	3 studies	28% ± 8%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
lung	18 studies	40% ± 15%	Explore
peripheral blood	12 studies	24% ± 6%	Explore
intestine	7 studies	42% ± 23%	Explore
heart	6 studies	23% ± 6%	Explore
kidney	5 studies	35% ± 18%	Explore
uterus	5 studies	59% ± 21%	Explore
brain	5 studies	34% ± 16%	Explore
esophagus	4 studies	30% ± 15%	Explore
breast	4 studies	53% ± 22%	Explore
prostate	4 studies	60% ± 14%	Explore
liver	4 studies	27% ± 11%	Explore
pancreas	3 studies	25% ± 3%	Explore
placenta	3 studies	47% ± 5%	Explore
ovary	3 studies	45% ± 26%	Explore
eye	3 studies	37% ± 16%	Explore
adipose	3 studies	36% ± 4%	Explore
lymph node	3 studies	42% ± 25%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
ovary	100%	25144.37	180 / 180	99%	405.94	426 / 430
lung	100%	16213.08	576 / 578	98%	246.93	1136 / 1155
bladder	100%	17203.14	21 / 21	96%	193.36	486 / 504
prostate	98%	15896.07	240 / 245	97%	231.32	485 / 502
esophagus	94%	10673.60	1364 / 1445	100%	394.48	183 / 183
thymus	98%	11264.81	638 / 653	96%	235.19	581 / 605
liver	96%	10536.08	216 / 226	96%	229.33	391 / 406
kidney	92%	9252.81	82 / 89	97%	251.84	875 / 901
intestine	95%	11136.41	915 / 966	93%	148.05	489 / 527
stomach	93%	9810.67	334 / 359	94%	224.41	270 / 286
uterus	89%	10076.02	152 / 170	95%	217.96	435 / 459
breast	100%	17480.24	458 / 459	76%	108.45	851 / 1118
pancreas	62%	4190.17	203 / 328	94%	160.75	168 / 178
adrenal gland	90%	6461.29	231 / 258	60%	77.48	139 / 230
skin	96%	10549.44	1730 / 1809	52%	51.85	245 / 472
brain	29%	1333.73	755 / 2642	72%	115.76	508 / 705
ureter	0%	0	0 / 0	100%	55.01	1 / 1
spleen	100%	11015.13	240 / 241	0%	0	0 / 0
adipose	100%	20459.66	1199 / 1204	0%	0	0 / 0
blood vessel	99%	17878.67	1316 / 1335	0%	0	0 / 0
tonsil	0%	0	0 / 0	96%	236.10	43 / 45
heart	81%	7368.36	694 / 861	0%	0	0 / 0
muscle	79%	7503.28	635 / 803	0%	0	0 / 0
peripheral blood	74%	11729.05	688 / 929	0%	0	0 / 0
eye	0%	0	0 / 0	49%	51.99	39 / 80
lymph node	0%	0	0 / 0	48%	39.04	14 / 29
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0006366	Biological process	transcription by RNA polymerase II
GO_0002244	Biological process	hematopoietic progenitor cell differentiation
GO_0006357	Biological process	regulation of transcription by RNA polymerase II
GO_0048839	Biological process	inner ear development
GO_0045669	Biological process	positive regulation of osteoblast differentiation
GO_0045595	Biological process	regulation of cell differentiation
GO_0045892	Biological process	negative regulation of DNA-templated transcription
GO_0140467	Biological process	integrated stress response signaling
GO_0045444	Biological process	fat cell differentiation
GO_0045944	Biological process	positive regulation of transcription by RNA polymerase II
GO_0005654	Cellular component	nucleoplasm
GO_0090575	Cellular component	RNA polymerase II transcription regulator complex
GO_0000785	Cellular component	chromatin
GO_0005634	Cellular component	nucleus
GO_0000978	Molecular function	RNA polymerase II cis-regulatory region sequence-specific DNA binding
GO_0001228	Molecular function	DNA-binding transcription activator activity, RNA polymerase II-specific
GO_0000981	Molecular function	DNA-binding transcription factor activity, RNA polymerase II-specific
GO_1990837	Molecular function	sequence-specific double-stranded DNA binding
GO_0042802	Molecular function	identical protein binding
GO_0005515	Molecular function	protein binding

IV. Literature review

[source]

Gene name	CEBPD
Protein name	CCAAT/enhancer-binding protein delta (C/EBP delta) (Nuclear factor NF-IL6-beta) (NF-IL6-beta) CEBPD protein
Synonyms
Description	FUNCTION: Transcription activator that recognizes two different DNA motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers . Important transcription factor regulating the expression of genes involved in immune and inflammatory responses . Transcriptional activator that enhances IL6 transcription alone and as heterodimer with CEBPB . .
Accessions	P49716 Q504X4 ENST00000408965.4

CEBPD report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review